SNGX News and Press, Soligenix Inc. From 07/27/22

Soligenix ( NASDAQ: SNGX ) said it received agreement from the U.S. Food & Drug Administration (FDA) on an initial pediatric study plan ((iPSP)) of its photodynamic therapy HyBryte (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL). The iPSP stipu...

Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J. , July 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company),...

HyBryte™ NDA Anticipated in H2 2022   New York, NY - ( NewMediaWire ) - July 26, 2022 - PCG Digital --  Late-stage biopharmaceutical company,  Soligenix, Inc. (Nasdaq: SNGX), has completed the largest placebo controlled, randomized Phase 3 trial ever...

HyBryte(TM) NDA Anticipated in H2 2022 New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the largest placebo controlled, randomized Phase 3 trial ever done in cutaneous T-cell lymphoma (C...

Soligenix ( NASDAQ: SNGX ) said it signed an exclusive license to supply its ricin antigen to SERB Pharmaceuticals to develop a novel therapy for ricin toxin poisoning. There is an unmet need for protection against this highly potent toxin for which there is no vaccine...

Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen PR Newswire SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen PRINCETON, N.J. , J...

HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology PR Newswire Published findings demonstrate that HyBryte ™ treatment statistically significantly reduced CTCL lesion size HyBryte ™ ...

Clinical-stage biotech Soligenix (NASDAQ:SNGX) added ~11% in the pre-market Tuesday after the company announced that the FDA cleared its investigational new drug (IND) application to start a mid-stage trial for SGX302, an experimental therapy for psoriasis. The Phase 2a trial design...

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis PR Newswire Enrollment on Track to Begin in 4 th Quarter of 2022 PRINCETON, N.J. , June 28, 2022 /PRNewswire/ -- S...

Strategy supports global need and has potential use in growing home healthcare market New York, New York--(Newsfile Corp. - June 7, 2022) - PCG Digital -- Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and com...